Tiotropium

證據等級: L5

預測適應症: 10 個

Tiotropium: From Chronic Obstructive Pulmonary Disease to Obstructive Lung Disease

One-Sentence Summary

Tiotropium is a long-acting muscarinic antagonist (LAMA) whose established global use is maintenance bronchodilator therapy for chronic obstructive pulmonary disease (COPD). The TxGNN model’s top prediction, Obstructive Lung Disease, is essentially an upper-level ontology term for this same disease space rather than a genuinely new therapeutic target — it is supported by 89 clinical trials and 20 publications in this evidence pack, including multiple completed Phase 3 RCTs. Critically, tiotropium is not currently registered with SAHPRA and has zero market authorizations in South Africa, and key Professional Information safety data is flagged as a Blocking data gap.

Quick Overview

Item	Content
Original Indication	Chronic Obstructive Pulmonary Disease (COPD) — internationally established maintenance bronchodilator indication; not captured in the SAHPRA licensing data because the product currently holds no South African registration
Predicted New Indication	Obstructive Lung Disease
TxGNN Prediction Score	99.99%
Evidence Level	L1
South Africa Market Status	Not Marketed
Number of SAHPRA Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

The evidence pack flags detailed mechanism-of-action data as a High-severity data gap (DG002). However, the pipeline’s own mechanistic analysis (attached to the closely related “chronic obstructive pulmonary disease” prediction, rank 5) already documents the pharmacology: tiotropium is a long-acting muscarinic (M1/M3) receptor antagonist that blocks acetylcholine-mediated bronchial smooth muscle contraction, producing sustained bronchodilation. This is described as the “core, already fully validated mechanism for COPD treatment — a direct relationship, not a speculative association.”

The relationship between the “original” and “predicted new” indication in this case is unusual: the model’s own rationale for rank 1 states that “Obstructive Lung Disease” is an upper-level/parent concept term for COPD and airway obstructive disease, and that this candidate represents “an extension of an already-approved mechanism naming, not a novel prediction.” This is corroborated by the fact that “chronic obstructive pulmonary disease” itself appears independently at rank 5 with an almost identical score (99.87%), the same L1 evidence level, and the same “Proceed with Guardrails” stage.

Because both predictions sit within tiotropium’s already-approved disease space, the mechanism is directly and extensively validated — including landmark trials such as the NEJM early-stage COPD study and multiple Cochrane systematic reviews. In practical terms, this evidence pack should be read as confirming tiotropium’s established utility in obstructive airway disease, not as surfacing a novel repurposing signal. For context, the model also generated several structurally or genetically implausible predictions for this drug (e.g., respiratory malformation, Rienhoff syndrome, tracheal stenosis, CD8α-deficiency-related infection susceptibility) — all scored L5 with a “Hold” recommendation, as none have a plausible mechanistic link to smooth-muscle bronchodilation.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00776984	Phase 3	Completed	453	Placebo-controlled trial of tiotropium Respimat (5 mcg/day) as add-on controller therapy over 48 weeks in severe persistent asthma — Grade A relevance
NCT01316913	Phase 3	Completed	872	GSK573719/GW642444 vs GSK573719 vs tiotropium over 24 weeks in COPD — large registrational-quality comparator trial, Grade A relevance
NCT00277264	Phase 3	Completed	914	SAFE study — one-year effect of 18 mcg tiotropium once daily on trough FEV1 vs placebo in COPD
NCT00144339	Phase 3	Completed	5,993	Large RCT assessing whether tiotropium slows the rate of lung-function decline in COPD
NCT00523991	Phase 4	Completed	457	24-week RCT of tiotropium + PRN albuterol vs placebo + PRN albuterol in maintenance-naïve COPD patients
NCT01012765	Phase 3	Completed	173	Crossover study using open-label tiotropium as active control vs indacaterol/placebo in moderate COPD
NCT01112241	Phase 4	Completed	17	Bronchodilator responsiveness to tiotropium in obliterative bronchiolitis post-HSCT — Grade B relevance (obstructive-disease subgroup)
NCT03199976	Phase 4	Terminated	80	Intermittent tiotropium vs fluticasone vs salbutamol alone for episode-free days in early childhood recurrent wheeze
NCT00515502	Phase 2	Completed	24	Dose-ascending safety/PK/PD study of GSK573719 using tiotropium 18 mcg as active comparator in COPD
NCT00279019	Phase 1	Completed	31	Safety/PK/PD comparison of GSK233705 vs tiotropium bromide in COPD patients

79 additional trials are recorded in the underlying evidence pack (SANCTR/PACTR identifiers were not present in the source data).

Literature Evidence

PMID	Year	Type	Journal	Key Findings
28877027	2017	RCT	The New England Journal of Medicine	Long-term tiotropium improves lung function and slows decline in mild/moderate, early-stage COPD
25046211	2014	Review (Cochrane)	Cochrane Database of Systematic Reviews	Systematic review confirming efficacy of tiotropium vs placebo across COPD symptom, exacerbation, and lung-function outcomes
26391969	2015	Review (Cochrane)	Cochrane Database of Systematic Reviews	Comparative review of tiotropium vs ipratropium bromide in stable COPD
32727455	2020	Review	Respiratory Research	Overview of tiotropium’s clinical development program supporting LAMA monotherapy as GOLD-recommended initial COPD treatment
12010082	2002	Review	Drugs	Establishes tiotropium’s pharmacology (M1/M2/M3 antagonism) and clinical profile improving lung function vs placebo/ipratropium in COPD
10069510	1999	Review	Life Sciences	Mechanistic and clinical profile of tiotropium (Spiriva) as first-line bronchodilator in obstructive lung disease
11281822	2001	Review	Expert Opinion on Investigational Drugs	Early clinical pharmacology review describing prolonged bronchodilator effect of tiotropium in Phase 2 studies
33095662	2021	Review	Current Medical Research and Opinion	Evidence review of tiotropium + olodaterol fixed-dose combination per GOLD 2020 recommendations for reducing COPD exacerbations
29206658	2018	Review	Current Opinion in Pulmonary Medicine	Review of lung-function trajectories in COPD, including pharmacologic intervention effects in early disease phases
23170031	2012	Review	The Annals of Pharmacotherapy	Review of efficacy/safety data for concomitant ipratropium and tiotropium use in COPD

South Africa Market Information

Tiotropium currently holds no SAHPRA registration — the evidence pack records 0 licenses and a market status of “Not Marketed.” There is no existing South African product, dosage form, or approved-indication text to summarize at this time.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

Note: this evaluation flags TFDA/SAHPRA-equivalent label warnings and contraindications as a Blocking data gap (DG001) — retrieval and parsing of the official Professional Information is required before this candidate can enter the S1 safety screening stage.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The mechanistic and clinical-trial/literature evidence base for tiotropium in obstructive airway disease is extensive and mature (L1, multiple completed Phase 3 RCTs plus Cochrane-level systematic reviews). However, this candidate is best understood as confirming an already-established indication rather than a novel repurposing discovery, and two structural blockers remain: the drug is not currently registered with SAHPRA (0 licenses), and label-level safety data (warnings/contraindications) is a documented Blocking gap. “Proceeding with guardrails” here should be read as proceeding toward a standard registration/importation review, not a research-validation pathway.

To proceed, the following is needed:

Retrieval and parsing of the SAHPRA/manufacturer Professional Information (PI) to close the Blocking safety data gap (DG001)
Formal documentation of mechanism of action from DrugBank or equivalent source to close the High-severity MOA gap (DG002)
A SAHPRA registration/import pathway assessment, since the product currently has zero South African market authorization
Clarification of route/formulation availability (inhaled capsule vs. Respimat soft-mist) suitable for the South African market
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.